Form 4: Carisma Therapeutics Inc. Director John Hohneker Reports Stock Option Grant
SEC Form 4 Filing
Director John Hohneker reports the acquisition of stock options in Carisma Therapeutics Inc.
Summary
- On April 1, 2024, John Hohneker, a director of Carisma Therapeutics Inc., reported the acquisition of stock options.
- The stock options grant the right to buy 38,700 shares of common stock at an exercise price of $2.09.
- The options vest in equal monthly installments over three years, starting April 1, 2024, contingent upon continued service to Carisma Therapeutics Inc.
- The options expire on April 1, 2034.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing related to stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of incentivizing management, but it's a routine event.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of earliest transaction (stock option grant) |
| 04/01/2024 | Vesting start date for the stock options |
| 04/01/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.